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Background:
Pancreatitis Associated With TTP:  A Cause or Effect?
Discussion:
In the majority of case reports of patients with pancreatitis and TTP, ADAMTS13 activity was only 
moderately reduced with no detectable inhibitor.2-3 These findings are suggestive of secondary 
TTP.
In this patient, the absence of a recognized etiology for pancreatitis, combined with marked 
thrombocytopenia on presentation and evidence of severe ADAMTS13 deficiency with an 
inhibitor, suggests acquired TTP.  To further support this interpretation, the patient had a relapse 
of TTP without further episodes of pancreatitis.
Current guidelines for treatment of acquired TTP suggest continuing EP for a minimum of 2 days 
after normalization of platelet counts.4 
 Although measurements of ADAMTS13 activity are not required for the diagnosis of TTP, they 
may help to discriminate between acquired versus secondary TTP.4
Patients with ADAMTS13 activity< 10% or an anti-ADAMTS13 antibody have been shown to 
have an increased risk of relapse.5 
The use of rituximab has been shown to reduce and delay the incidence of relapse, and has 
been shown to be an effective treatment for refractory TTP.6 
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A 60-year-old Caucasian male presented to the ER with a 2 week history of sharp epigastric 
pain. Abdominal exam revealed a soft, non-distended abdomen with epigastric tenderness. 
Initial laboratory examination showed a Hb of 13.5 g/dL and platelets of 17,000/uL. Lipase was 
elevated at 2473 u/L and total bilirubin was elevated to 2.6 mg/dl with an increased indirect 
fraction. LDH was elevated at 1432 IU/L.  Numerous schistocytes were observed on peripheral 
smear.  CT scan of the abdomen showed findings consistent with acute pancreatitis and MRCP 
showed no evidence of cholelithiasis, or choledocholithiasis.  ADAMTS13 activity was less than 
10% with an elevated ADAMTS13 antibody at 41 U/ mL (Reference range < 12U/mL).  Patient 
was started on prednisone 1mg/kg daily in addition to daily EP.  After five days of EP, there 
was normalization of his platelets.  EP was continued 
two days post platelet normalization and patient was 
discharged home on a tapering dose of steroids. 
Patient returned to the ER 2 days after discharge 
with a recurrence of thrombocytopenia. On this 
admission, patient had no reoccurrence of abdominal 
pain and lipase was normal. EP was reinitiated and 
he required a 5 week hospital stay due to refractory 
thrombocytopenia. He was consequently started 
on rituximab and completed 4 weekly doses. Post 
rituximab, platelets stabilized and remained within the 
normal range.
Conclusion:
This case demonstrates an acquired TTP that presented with pancreatitis.  In patients 
presenting with features of TTP and other systemic symptoms, the presence of a significantly 
decreased ADAMTS13 level with the presence of an inhibitor may be used to discriminate 
between acquired TTP and secondary TTP and therefore help to distinguish those patients who 
would most benefit from EP and glucocorticoids. In addition,  ADAMTS13 levels help to identify 
those patients who are at increased risk for relapse. This patient with severe ADAMTS13 activity 
quickly relapsed after discontinuing EP. In addition, this case demonstrates the role of rituximab 
in relapsed/refractory TTP. 
Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by platelet aggregation 
and the formation of platelet thrombi, leading to thrombocytopenia and microangiopathic 
hemolytic anemia, with or without renal failure or neurologic abnormalities, and without another 
cause identified.1 
Acute TTP can be acquired or secondary. Secondary causes of TTP are well documented and 
include medication, infection, malignancy and autoimmune disorders.
Pancreatitis has been shown to be associated with TTP, however, it still remains unclear what 
the causal relationship is between the two.2-3
TTP remains a medical emergency with an accurate and quick diagnosis necessary to reduce 
mortality. Glucocorticoids and daily exchange plasmapheresis (EP) are standard treatment; 
rituximab and other immunosuppressive agents are generally saved for refractory cases.4
Figure 1: CT scan of abdomen showing acute pancreatis.
